Literature DB >> 32184110

Derivation and Validation of a Diagnostic Prediction Tool for Interstitial Lung Disease.

Janelle Vu Pugashetti1, Aleksander Kitich2, Shehabaldin Alqalyoobi1, Anne-Catherine Maynard-Paquette3, David Pritchard4, Julia Graham4, Noelle Boctor4, Andrea Kulinich1, Elyse Lafond5, Elena Foster1, Cesar Mendez1, Saad Choudhry1, Jean Chalaoui6, Julie Morisset3, Michael Kadoch7, Justin M Oldham8.   

Abstract

BACKGROUND: Interstitial lung disease (ILD) results in high morbidity and health-care utilization. Diagnostic delays remain common and often occur in nonpulmonology settings. Screening for ILD in these settings has the potential to reduce diagnostic delays and improve patient outcomes. RESEARCH QUESTION: This study sought to determine whether a pulmonary function test (PFT)-derived diagnostic prediction tool (ILD-Screen) could accurately identify incident ILD cases in patients undergoing PFT in nonpulmonology settings. STUDY DESIGN AND METHODS: Clinical and physiologic PFT variables predictive of ILD were identified by using iterative multivariable logistic regression models. ILD status was determined by using a multi-reader approach. An ILD-Screen score was generated by using final regression model coefficients, with a score ≥ 8 considered positive. ILD-Screen test performance was validated in an independent external cohort and applied prospectively to PFTs over 1 year to identify incident ILD cases at our institution.
RESULTS: Variables comprising the ILD-Screen were age, height, total lung capacity, FEV1, diffusion capacity, and PFT indication. The ILD-Screen showed consistent test performance across cohorts, with a sensitivity of 0.79 and a specificity of 0.83 when applied prospectively. A positive ILD-Screen strongly predicted ILD (OR, 18.6; 95% CI, 9.4-36.9) and outperformed common ILD clinical features, including cough, dyspnea, lung crackles, and restrictive lung physiology. Prospective ILD-Screen application resulted in a higher proportion of patients undergoing chest CT imaging compared with a historical control cohort (74% vs 56%, respectively; P = .003), with a significantly shorter median time to chest CT imaging (5.6 vs 21.1 months; P < .001).
INTERPRETATION: The ILD-Screen showed good test performance in predicting ILD across diverse geographic settings and when applied prospectively. Systematic ILD-Screen application has the potential to reduce diagnostic delays and facilitate earlier intervention in patients with ILD.
Copyright © 2020 American College of Chest Physicians. All rights reserved.

Entities:  

Keywords:  idiopathic pulmonary fibrosis; interstitial lung abnormalities; interstitial lung disease; pulmonary fibrosis; screening

Mesh:

Year:  2020        PMID: 32184110      PMCID: PMC7469246          DOI: 10.1016/j.chest.2020.02.044

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  30 in total

1.  Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris.

Authors:  Boris Duchemann; Isabella Annesi-Maesano; Camille Jacobe de Naurois; Shreosi Sanyal; Pierre-Yves Brillet; Michel Brauner; Marianne Kambouchner; Sophie Huynh; Jean Marc Naccache; Raphael Borie; Jacques Piquet; Arsène Mekinian; Jerôme Virally; Yurdagul Uzunhan; Jacques Cadranel; Bruno Crestani; Olivier Fain; Francois Lhote; Robin Dhote; Nathalie Saidenberg-Kermanac'h; Paul-André Rosental; Dominique Valeyre; Hilario Nunes
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

2.  Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.

Authors:  Yossra A Suliman; Rucsandra Dobrota; Dörte Huscher; Thi D L Nguyen-Kim; Britta Maurer; Suzana Jordan; Rudolf Speich; Thomas Frauenfelder; Oliver Distler
Journal:  Arthritis Rheumatol       Date:  2015-12       Impact factor: 10.995

3.  High-Attenuation Areas on Chest Computed Tomography and Clinical Respiratory Outcomes in Community-Dwelling Adults.

Authors:  Anna J Podolanczuk; Elizabeth C Oelsner; R Graham Barr; Elana J Bernstein; Eric A Hoffman; Imaani J Easthausen; Karen Hinckley Stukovsky; Arindam RoyChoudhury; Erin D Michos; Ganesh Raghu; Steven M Kawut; David J Lederer
Journal:  Am J Respir Crit Care Med       Date:  2017-12-01       Impact factor: 21.405

4.  Idiopathic Pulmonary Fibrosis.

Authors:  David J Lederer; Fernando J Martinez
Journal:  N Engl J Med       Date:  2018-08-23       Impact factor: 91.245

5.  Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

Authors:  Oliver Distler; Kristin B Highland; Martina Gahlemann; Arata Azuma; Aryeh Fischer; Maureen D Mayes; Ganesh Raghu; Wiebke Sauter; Mannaig Girard; Margarida Alves; Emmanuelle Clerisme-Beaty; Susanne Stowasser; Kay Tetzlaff; Masataka Kuwana; Toby M Maher
Journal:  N Engl J Med       Date:  2019-05-20       Impact factor: 91.245

6.  All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement.

Authors:  Aryeh Fischer; Amanda M Kong; Jeffrey J Swigris; Ashley L Cole; Karina Raimundo
Journal:  J Rheumatol       Date:  2017-11-15       Impact factor: 4.666

7.  Underreporting of Interstitial Lung Abnormalities on Lung Cancer Screening Computed Tomography.

Authors:  Justin M Oldham; Ayodeji Adegunsoye; Satinderpal Khera; Elyse Lafond; Imre Noth; Mary E Strek; Michael Kadoch; Jonathan H Chung
Journal:  Ann Am Thorac Soc       Date:  2018-06

8.  Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis.

Authors:  Julie Morisset; Kerri A Johannson; Eric Vittinghoff; Carlos Aravena; Brett M Elicker; Kirk D Jones; Charlene D Fell; Helene Manganas; Bruno-Pierre Dubé; Paul J Wolters; Harold R Collard; Christopher J Ryerson; Brett Ley
Journal:  Chest       Date:  2016-11-03       Impact factor: 9.410

9.  Association Between Interstitial Lung Abnormalities and All-Cause Mortality.

Authors:  Rachel K Putman; Hiroto Hatabu; Tetsuro Araki; Gunnar Gudmundsson; Wei Gao; Mizuki Nishino; Yuka Okajima; Josée Dupuis; Jeanne C Latourelle; Michael H Cho; Souheil El-Chemaly; Harvey O Coxson; Bartolome R Celli; Isis E Fernandez; Oscar E Zazueta; James C Ross; Rola Harmouche; Raúl San José Estépar; Alejandro A Diaz; Sigurdur Sigurdsson; Elías F Gudmundsson; Gudny Eiríksdottír; Thor Aspelund; Matthew J Budoff; Gregory L Kinney; John E Hokanson; Michelle C Williams; John T Murchison; William MacNee; Udo Hoffmann; Christopher J O'Donnell; Lenore J Launer; Tamara B Harrris; Vilmundur Gudnason; Edwin K Silverman; George T O'Connor; George R Washko; Ivan O Rosas; Gary M Hunninghake
Journal:  JAMA       Date:  2016-02-16       Impact factor: 56.272

10.  "Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease.

Authors:  Giacomo Sgalla; Simon L F Walsh; Nicola Sverzellati; Sophie Fletcher; Stefania Cerri; Borislav Dimitrov; Dragana Nikolic; Anna Barney; Fabrizio Pancaldi; Luca Larcher; Fabrizio Luppi; Mark G Jones; Donna Davies; Luca Richeldi
Journal:  BMC Pulm Med       Date:  2018-06-18       Impact factor: 3.317

View more
  2 in total

1.  Clinical implication of interstitial lung abnormality in elderly patients with early-stage non-small cell lung cancer.

Authors:  Seong Woo Cho; Won Gi Jeong; Jong Eun Lee; In-Jae Oh; Sang Yun Song; Hye Mi Park; Hyo-Jae Lee; Yun-Hyeon Kim
Journal:  Thorac Cancer       Date:  2022-02-11       Impact factor: 3.500

2.  Response.

Authors:  Janelle Vu Pugashetti; Gabrielle Echt; Samantha C Nguyen; Justin M Oldham
Journal:  Chest       Date:  2021-03       Impact factor: 9.410

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.